Skip to the main content.

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

Dr. Dave Seaward : 28 February 2022

Cell and Gene Therapy Series. Part 4 - Managing costs and scale-up risks for medical devices

As we continue to explore the world of cell and gene therapy, we now take a look at managing costs and scale up risks for medical devices.

Author Dave Seward, discusses how the principles of Quality by Design (QbD) and Design for Manufacture (DfM) can be applicable to ATMPs. Read this blog now!
Mark Wilson - Navigating Innovation in a Slow-Moving Pharma Industry

Mark Wilson - Navigating Innovation in a Slow-Moving Pharma Industry

Georgia Lewis: 11 March 2026

Mark Wilson - Presentation at UK Pharmaceutical & MedTech Innovations event.ISPE UK Affiliate - 12/2/2026 Listening to Mark’s reflections on his 20...

Read More
Optimising Cryovial Filling and Cryopreservation for Reliable Cell Functionality

Optimising Cryovial Filling and Cryopreservation for Reliable Cell Functionality

3P innovation: 10 March 2026

An Integrated Equipment Workflow for Consistent Post-Thaw Viability and Function Recovery

Read More
The challenges of developing combination products: Regulatory complexity and the case for a holistic development strategy

The challenges of developing combination products: Regulatory complexity and the case for a holistic development strategy

Dr. Dave Seaward: 15 February 2026

Drug–device combination products are becoming a defining feature of modern pharmaceutical portfolios, shaping how therapies differentiate, extend...

Read More